Screener
NewAmsterdam Pharma Company NAMS Operating Lease Liability, Current
Operating Lease Liability, Current at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | 5,422 | 8,970 |
| Accrued expenses and other current liabilities | 10,277 | 15,422 |
| Deferred revenue, current | 2,797 | 3,987 |
| Lease liability, current | 26 | 136 |
| Derivative warrant liabilities | 54,452 | 57,272 |
| Total current liabilities | 72,974 | 85,787 |
| Lease liability, net of current portion | 56 | 66 |
| Total liabilities | 73,030 | 85,853 |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's operating lease liability, current?
- NewAmsterdam Pharma Company (NAMS) reported operating lease liability, current of $26K in Q2 2026.
- How has NewAmsterdam Pharma Company's operating lease liability, current changed year-over-year?
- NewAmsterdam Pharma Company's operating lease liability, current decreased by 88.4% year-over-year, from $225K to $26K.
- What is the long-term trend for NewAmsterdam Pharma Company's operating lease liability, current?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's operating lease liability, current has grown at a 27.3% compound annual growth rate (CAGR), from $66K to $136K.
- What does operating lease liability, current mean?
- Operating Lease Liability, Current as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's operating lease liability, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude